People with Type 1 diabetes are estimated to make up to 180 more decisions a day than someone without the disease, according to a study from Stanford University. Each meal, workout, or night’s sleep ...
Dexcom, Inc, has issued a recall for G7 Apps and ONE+ Apps because of a software design error failing to alert users of unexpected sensor failures. This recall ...
DexCom's returns over the past decade have been solid, but not quite on par with the market's. The company has encountered some headwinds in recent years that have sunk its stock price. Despite the ...
DexCom, Inc. (NASDAQ:DXCM) is one of the best strong buy healthcare stocks to buy now. On July 16, Mizuho analyst Anthony Petrone raised the firm’s price target on DexCom, Inc. (NASDAQ:DXCM) to $100 ...
Dexcom has recalled its G6, G7, ONE, and ONE+ continuous glucose monitor (CGM)receivers due to a speaker malfunction that could cause missed low or high blood sugar alerts. The recall, for which ...
On Thursday, Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. U.S. revenue rose by 4%, while ...
Four years ago, my life changed after a heart attack at the age of 33. While a quick coronary angioplasty meant my heart was mostly fine, the tests conducted at the same time revealed a bigger chronic ...
DexCom is a leader in the continuous glucose monitoring (CGM) systems market. They aren't the only kinds of devices that help diabetes patients keep track of their blood glucose levels -- a necessary ...
Dexcom has experienced some intense highs and lows this year. The highs were the release of the Stelo, an over-the-counter glucose monitor with the lows being a troubling 2nd quarter that caused ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results